City Union Bank Limited (CUB) has received RBI approval for Kotak Mahindra Bank Limited to acquire up to 9.99% of its paid-up share capital. The approval is subject to compliance with Banking Regulation Act provisions and RBI's 2025 directions on shareholding.
The Reserve Bank of India approved Kotak Mahindra Bank's proposal to acquire up to a 9.99% stake in Jammu and Kashmir Bank. The approval is valid for one year and is subject to compliance with Banking Regulation Act provisions. Kotak Mahindra Bank must maintain at least a 5% holding once acquired unless prior RBI approval is obtained.
ICICI Bank received RBI approval for HDFC Bank Limited to acquire up to 9.95% of its paid-up share capital or voting rights. The approval is valid for one year and remains subject to statutory compliance. This development highlights significant inter-bank equity participation within the Indian private banking sector.
The Reserve Bank of India (RBI) has approved Kotak Mahindra Bank Limited's proposal to acquire an aggregate holding of up to 9.99% in Federal Bank Ltd. The approval, received on May 06, 2026, is subject to compliance with Banking Regulation Act provisions and other regulatory guidelines.
Facor Alloys Ltd received in-principle approval from East Coast Railway to migrate its existing railway siding to the Gati Shakti Cargo Terminal (GCT) framework. This regulatory milestone allows the company to operate under the new GCT Policy, subject to standard railway compliance and approvals.
RBL Bank received RBI approval for amending its Articles of Association concerning director nomination rights for Emirates NBD Bank. This regulatory milestone supports the proposed preferential equity issue to the Investor, which remains subject to further customary conditions and approvals.
AU Small Finance Bank received RBI approval for Kotak Mahindra Bank Limited to acquire up to a 9.99% aggregate holding in the bank. The approval is subject to compliance with the Banking Regulation Act and SEBI guidelines. This represents a significant strategic investment by a major private sector peer.
HDFC Bank received RBI approval for its group entities to acquire up to 9.95% aggregate holding in ICICI Bank and Kotak Mahindra Bank. The approval is valid until May 5, 2027. The bank noted these investments by group entities like HDFC Mutual Fund and HDFC Life are made in the normal course of business.
Omaxe Ltd's subsidiary, M/s Omaxe Garv Buildtech Private Limited, received RERA registration certificates for two projects: Commercial-3 Block-1 and Commercial-3 Block-2 in Lucknow. These approvals, valid until December 17, 2030, enable the company to sell, transfer, or advertise these commercial projects, strengthening its operational compliance and brand value in the region.
Motilal Oswal Financial Services' subsidiary, MOAMC, received PFRDA approval to act as a Sponsor of a Pension Fund under the National Pension System. This allows MOAMC to establish a separate pension fund entity for managing retirement assets, marking a significant entry into India's long-term pension management space.
Privi Speciality Chemicals Limited received a 'no objection' observation letter from NSE for its merger scheme with Privi Fine Sciences and Privi Biotechnologies. Approval from BSE is currently awaited. The amalgamation remains subject to further regulatory and statutory clearances.
Steel Exchange India Limited received a 5-year renewal of approval from the Military Engineer Services (MES), Ministry of Defence. This permits the continued manufacturing and supply of SIMHADRI TMT bars (grades Fe 500D and Fe 500D HCRM) from its Vizianagaram plant. The renewal sustains the company's participation in government and infrastructure projects.
Auro Laboratories Limited received an 'Attestation of Inspection' from the EDQM for its MIDC Tarapur facility. The certification confirms compliance with EU Good Manufacturing Practice (GMP) standards for Metformin Hydrochloride. This regulatory milestone validates the facility's quality standards for European market requirements.
Auro Laboratories Ltd has received a Certificate of GMP Compliance (No. 26-0002) from Swissmedic for its manufacturing facility in Tarapur, Maharashtra. The certification confirms compliance with GMP requirements under the EU-Switzerland Mutual Recognition Agreement, validating the plant's quality standards for therapeutic products.
Niyogin Fintech Limited received 'in-principle' approval from the RBI on April 30, 2026, for its Composite Scheme of Arrangement and Amalgamation. This follow-up disclosure confirms regulatory progress for the scheme involving Niyogin Finserv and iServeU Technology.
Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received final USFDA approval for its Calcium Gluconate Injection USP. The product addresses acute symptomatic hypocalcemia and targets a US market with annual sales of approximately ₹674.5 Crore ($71 million). This approval strengthens the company's injectable portfolio in the regulated US market.
Lupin Limited received U.S. FDA approval for Glycerol Phenylbutyrate Oral Liquid, a bioequivalent version of Ravicti. The reference product had annual U.S. sales of approximately ₹3201.50 Crore (USD 337 million) in 2025. The drug is indicated for chronic management of urea cycle disorders, strengthening Lupin's specialty generic portfolio in the U.S. market.
Anuh Pharma Ltd received WHO Prequalification approval for its anti-malarial API, Amodiaquine Hydrochloride USP. This approval allows the company to supply international markets, including WHO-procured and donor-funded programmes, consolidating its position as a preferred global supplier.
RBL Bank received SEBI's prior approval for a change in control related to a proposed preferential equity investment by Emirates NBD Bank. The transaction remains subject to other regulatory approvals and customary conditions. This approval marks a significant milestone in completing the strategic investment process.
Beacon Trusteeship Limited has been granted registration as a Debenture Trustee in the International Financial Services Centre (IFSC) by the IFSCA. This allows the company to expand its debenture trustee activities through a branch office in GIFT City, Gujarat. The registration is valid from May 4, 2026.
Meghmani Organics Limited's subsidiary, MCNL, received Ministry of Agriculture approval to manufacture Nano DAP, Nano NPK, and Nano Zinc fertilizers. Production will occur at the existing Sanand facility in Gujarat without additional capital expenditure. Commercial operations are slated to begin during the upcoming Kharif season, strengthening the company's sustainable crop nutrition portfolio.
Meghmani Organics Limited received approval from the Ministry of Agriculture and Farmers Welfare to manufacture Nano DAP, Nano NPK, and Nano Zinc. Production will occur at its Sanand facility in Gujarat via subsidiary Meghmani Crop Nutrition Limited. Commercial production is slated for the upcoming Kharif season without requiring additional capital expenditure.
Niyogin Fintech Limited received in-principle approval from the RBI for its Composite Scheme of Arrangement and Amalgamation involving Niyogin Finserv and iServeU Technology. This regulatory milestone advances the merger process, though implementation remains subject to further approvals from the NCLT, shareholders, and creditors.
OneSource Specialty Pharma's partner, Orbicular, received Health Canada approval for a generic version of Ozempic (semaglutide). This marks the second generic semaglutide approval in Canada, the world's second-largest market for the drug. OneSource will support commercial supply from its FDA-approved Bengaluru facility, strengthening its global CDMO position in complex injectables.
Vilas Transcore Limited received Consolidated Consent and Authorization (CCA-Fresh) from the Gujarat Pollution Control Board for its new industrial plant in Vadodara. This regulatory milestone enables the company to commence manufacturing products at the facility. The plant is located at Survey Nos. 419 & 420, Village Ganpatpura, Taluka Karjan.
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received marketing authorization (NOC) from Health Canada for its Bevacizumab biosimilar, Bevqolva™. This regulatory approval follows earlier UK authorization and commercial launch. The biosimilar, used to treat colorectal and lung cancers, will be available in 100 mg and 400 mg formulations, strengthening Aurobindo's global biosimilar portfolio.
V R Infraspace Limited was granted a Category 'A' Electrical Contractor License by the Government of Madhya Pradesh. Valid until December 31, 2028, this approval authorizes the company to perform all types of electrical installation work in the state, including high-voltage projects exceeding 33 kilovolts.
Jay Bee Laminations Limited received manufacturer approval from Power Grid Corporation of India Limited (PGCIL). The approval covers CRGO coils slitting and laminations cutting for transformers/reactors up to 765 kV class. Valid until April 29, 2027, this enables participation in POWERGRID projects, strengthening the company's technical qualifications and market position.
CARE Ratings Limited received SEBI authorization to commence services as a Past Risk and Return Verification Agency (PaRRVA) from May 4, 2026. This follows the successful completion of a pilot phase initiated under SEBI's April 2025 circular.
RBL Bank received prior approval from SEBI for a change in control related to a proposed investment by Emirates NBD Bank. The transaction involves a preferential issue of equity shares and remains subject to other regulatory approvals and customary conditions.